Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).

Heather M. Moore,Valentina Boni,Meritxell Bellet,Begoña Bermejo de las Heras,Maria Gion Cortés,Catherine Oakman,Peter Schmid,Xuan Bich Trinh,Duncan Wheatley,Komal Jhaveri,Peter Kabos,Elgene Lim,Thierry Velu,Ciara Metcalfe,Mary Gates,Ching-Wei Chang,John Bond,Leonard D. Goldstein,Jennifer O. Lauchle,Aditya Bardia

Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).

2021

577Background: Modulation of ER activity and/or estrogen synthesis is the mainstay therapeutic strategy in ER+ BC treatment. Giredestrant is a highly potent, nonsteroidal oral selective ER degrader...

Keywords:

Window of opportunity
Internal medicine
therapeutic strategy
Oncology
Medicine
Estrogen receptor
Estrogen synthesis
Breast cancer
HER2 negative
Pharmacodynamics
Nonsteroidal

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations